2020
Cannabinoids
De Aquino J, Arnaout B. Cannabinoids. 2020, 153-167. DOI: 10.1007/978-3-030-33404-8_10.Peer-Reviewed Original ResearchCannabis use disorderUse of cannabinoidsPotential pharmacokinetic interactionsEffects of cannabinoidsDose-dependent effectPharmacokinetic interactionsPsychotropic medicationsRisk factorsPsychosocial treatmentsPsychiatric disordersUse disordersAddiction specialistsHealthcare providersPsychomotor functioningCannabinoidsSynthetic cannabinoidsDisordersMedicinal useMedicationsPatientsProgressionBrief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians’ Confidence and Readiness to Address Substance Use Disorders
Iheanacho T, Bommersbach T, Fuehrlein B, Arnaout B, Dike C. Brief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians’ Confidence and Readiness to Address Substance Use Disorders. Community Mental Health Journal 2020, 56: 1429-1435. PMID: 32062717, PMCID: PMC7429311, DOI: 10.1007/s10597-020-00586-8.Peer-Reviewed Original ResearchConceptsSubstance use disordersMedication-assisted treatmentCommunity mental health cliniciansMental health cliniciansHealth cliniciansPost-training questionnairesUse disordersDisease modelsRoutine practiceCliniciansFactor 1Factor 2Brief trainingDisordersSignificant changesQuestionnaireLimited awarenessTreatmentPublic sector settingsAddictionPreMedicationsPatientsLow confidenceDisease
2018
Alcohol withdrawal hallucinations in the general population, an epidemiological study
Stephane M, Arnaout B, Yoon G. Alcohol withdrawal hallucinations in the general population, an epidemiological study. Psychiatry Research 2018, 262: 129-134. PMID: 29433107, DOI: 10.1016/j.psychres.2018.02.021.Peer-Reviewed Original ResearchConceptsOdds ratioBrain developmentHigher odds ratioLogistic regression analysisMost psychiatric illnessesNational Epidemiologic SurveyAlcohol withdrawalClinical patternWithdrawal seizuresPsychiatric comorbidityMechanisms of hallucinationsPsychiatric illnessUnmarried subjectsEpidemiological studiesGeneral populationEpidemiologic SurveyRelated conditionsAnxiety disordersLow levelsSevere exposureHallucinationsSocial isolationRegression analysisAfrican AmericansSuch historyDescription of a Comprehensive Addiction Rotation at a Psychiatry Residency Program
Arnaout B, Muvvala S, Rohrbaugh R, Petrakis I. Description of a Comprehensive Addiction Rotation at a Psychiatry Residency Program. Academic Psychiatry 2018, 42: 313-316. PMID: 29302930, DOI: 10.1007/s40596-017-0858-2.Peer-Reviewed Original Research
2017
Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder
Feeley RJ, Arnaout B, Yoon G. Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 729-730. PMID: 29028689, DOI: 10.1097/jcp.0000000000000794.Peer-Reviewed Original ResearchMotivational Interviewing for Clinical Practice: Just Do It
Marienfeld, C, Arnaout, B, Levounis, P. Motivational Interviewing for Clinical Practice: Just Do It. Psychiatric News 2017, 52: 1-1. DOI: 10.1176/appi.pn.2017.3a20.Peer-Reviewed Original ResearchMotivational Interviewing for Clinical Practice
Levounis P, Arnaout B, Marienfeld C. Motivational Interviewing for Clinical Practice. 2017 DOI: 10.1176/appi.books.9781615371860.Peer-Reviewed Original Research- Ponce Martinez, C., Arnaout, B., Martino, S. Fundamentals of Motivational Interviewing. In Motivational Interviewing for Clinical Practice, eds. Levounis, P., Arnaout, B., Marienfeld,C. American Psychiatric Association Publishing. 2017.Peer-Reviewed Original Research
- Levounis, P., Arnaout, B., Marienfled, C., eds. Motivational Interviewing for Clinical Practice. American Psychiatric Association Publishing. 2017.Peer-Reviewed Original Research
- Lynch, M., Arnaout, B., Rosenthal, R.N. Integrating Motivational Interviewing with Other Psychotherapies. In Motivational Interviewing for Clinical Practice, eds. Levounis, P., Arnaout, B., Marienfeld,C. American Psychiatric Association Publishing. 2017.Peer-Reviewed Original Research
2013
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski E, Jane J, O’Brien E, Edens E, Arnaout B, Kerfoot K, Keegan K, Weiner J, Russo M, Petrakis I. Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. Journal Of Dual Diagnosis 2013, 9: 301-310. DOI: 10.1080/15504263.2013.835163.Peer-Reviewed Original ResearchDepressive symptomsAlcohol dependenceDual diagnosisRates of smokingMain outcome variablesSymptoms of depressionTreatment of peopleTreatment trialsComorbid depressionMecamylamineSide effectsNonsmokersSmokingSymptomsOutcome variablesBest treatmentDrinking outcomesDepressionPlaceboSmokersFurther studiesSignificant differencesDiagnosisParticipantsTreatment- Ralevski, E., Jane, J.S., O’Brien, E., Edens, E., Arnaout, B., Kerfoot, K., Keegan, K., Weiner, J., Russo, M., Petrakis, I. Mecamylamine for treatment of people with dual diagnosis of depression and alcohol dependence. Journal of Dual Diagnosis. 2013, 9:301-310.Peer-Reviewed Original Research
2011
Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
Ralevski E, O’Brien E, Jane JS, Dwan R, Dean E, Edens E, Arnaout B, Keegan K, Drew S, Petrakis I. Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. Journal Of Dual Diagnosis 2011, 7: 64-73. PMID: 26954912, DOI: 10.1080/15504263.2011.569440.Peer-Reviewed Original ResearchEfficacy of acamprosateAlcohol dependenceSchizophrenia spectrum disordersMedication treatmentComorbid schizophreniaSignificant group x time interactionGroup x time interactionComorbid alcohol dependenceAlcohol use disorderSymptoms of schizophreniaX time interactionAcamprosate groupComorbid conditionsTreatment trialsAbstinent patientsClinical trialsSpectrum disorderAcamprosateGeneral populationUse disordersPatientsSchizoaffective disorderPositive symptomsSchizophrenic symptomsConsecutive days
2010
Sedative-Hypnotics and Anxiolytics
Arnaout B, Petrakis I. Sedative-Hypnotics and Anxiolytics. 2010, 511-523. DOI: 10.1007/978-1-4419-0338-9_23.Peer-Reviewed Original ResearchCentral nervous system depressantsPsychiatric adverse eventsGroup of medicationsNon-benzodiazepine hypnoticsNon-medical useAdverse eventsSexual dysfunctionSleep disordersSedative hypnoticsPsychotic manifestationsCognitive disordersTherapeutic valueGeneral medicineAnxiety disordersMedicationsDisordersAnxiolyticsDeleterious effectsAbuseHypnoticsDysfunctionBenzodiazepinesEpidemiologyIntoxicationNeurologyEscitalopram versus placebo in the treatment of dysthymic disorder
Hellerstein DJ, Batchelder ST, Hyler S, Arnaout B, Toba C, Benga I, Gangure D. Escitalopram versus placebo in the treatment of dysthymic disorder. International Clinical Psychopharmacology 2010, 25: 143-148. PMID: 21811192, DOI: 10.1097/yic.0b013e328333c35e.Peer-Reviewed Original ResearchConceptsHamilton Depression Rating ScaleDysthymic disorderGlobal assessmentSelective serotonin reuptake inhibitorsClinical Global Impressions-SeveritySuperiority of escitalopramPercentage of respondersPlacebo-treated individualsSerotonin reuptake inhibitorsDepression Rating ScaleStructured Clinical InterviewPercentage of participantsLarger study sampleItem total scoresSocial Adjustment ScaleAcute efficacyEscitalopram doseHDRS-24Active medicationReuptake inhibitorsWeek 12Inclusion criteriaSecondary measuresEscitalopramClinical Interview- Arnaout, B., Martino, S. Fundamentals of Motivation and Change. In Handbook of Motivation and Change: A Practical Guide for Clinicians, eds. Levounis, P., Arnaout, B. American Psychiatric Publishing, Inc. 2010.Peer-Reviewed Original Research
- Arnaout, B., Petrakis, I. Sedative-Hypnotics and Anxiolytics. In Addiction Medicine: Science and Practice, ed. B. A. Johnson. Springer. 2010.Peer-Reviewed Original Research
- Levounis, P., Arnaout, B., eds. Handbook of Motivation and Change: A Practical Guide for Clinicians. American Psychiatric Publishing, Inc. 2010.Peer-Reviewed Original Research
- Edens, E.L., Ross, D., Drew, S., LaPaglia, D., Pilkey, D., Arnaout, B., Petrakis, I. Model Curriculum Award for Alcohol Use Disorders at the Residency Training Program in Psychiatry at Yale School of Medicine, awarded by the American Association of Directors of Psychiatric Residency Training (AADPRT). 2010.Peer-Reviewed Original Research
2008
Does a History of Alcohol Use Disorder Affect Response to Antidepressant Medication in Patients With Dysthymic Disorder?
Arnaout B, Batchelder S, Rosenthal R, Hyler S, Hellerstein D. Does a History of Alcohol Use Disorder Affect Response to Antidepressant Medication in Patients With Dysthymic Disorder? Journal Of Dual Diagnosis 2008, 4: 377-393. DOI: 10.1080/15504260802086842.Peer-Reviewed Original ResearchLifetime alcohol use disorderAlcohol use disorderDysthymic disorderUse disordersBaseline Hamilton Depression Rating ScaleHamilton Depression Rating ScaleRating ScaleWeeks of treatmentWeeks of pharmacotherapyDepression Rating ScaleHDRS-24Medication trialsAlcoholic patientsAdult outpatientsRate of responseLifetime historySecondary analysisDisordersGreater decreaseRemissionPharmacotherapyPatientsAdequate evaluationTreatmentPreliminary findings